HRP20200990T1 - Sastavi za poboljšanje stanične vijabilnosti i postupci za njihovu upotrebu - Google Patents
Sastavi za poboljšanje stanične vijabilnosti i postupci za njihovu upotrebu Download PDFInfo
- Publication number
- HRP20200990T1 HRP20200990T1 HRP20200990TT HRP20200990T HRP20200990T1 HR P20200990 T1 HRP20200990 T1 HR P20200990T1 HR P20200990T T HRP20200990T T HR P20200990TT HR P20200990 T HRP20200990 T HR P20200990T HR P20200990 T1 HRP20200990 T1 HR P20200990T1
- Authority
- HR
- Croatia
- Prior art keywords
- pba
- pharmaceutically acceptable
- acceptable salt
- tudca
- use according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 12
- 238000000034 method Methods 0.000 title claims 11
- 230000003833 cell viability Effects 0.000 title 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 54
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 30
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims 30
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 25
- 230000037396 body weight Effects 0.000 claims 11
- 230000004770 neurodegeneration Effects 0.000 claims 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 230000004792 oxidative damage Effects 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Claims (16)
1. Sastav koji obuhvaća efikasnu količinu tauroursodezoksikolne kiseline (TUDCA) ili njenu farmaceutski prihvatljivu sol, i efikasnu količinu 4-fenilbutirične kiseline (4-PBA) ili njenu farmaceutski prihvatljivu sol, za upotrebu u postupku liječenja subjekta koji ima oboljenje ili je u riziku od neurodegenerativnog oboljenja.
2. Sastav za upotrebu prema patentnom zahtjevu 1, pri čemu su TUDCA i 4-PBA u sastavu prisutni u efikasnoj količini da bi se smanjilo oksidativno oštećenje izazvano reaktivnim metabolitom kisika unutar stanice subjekta.
3. Sastav za upotrebu prema patentnom zahtjevu 2, pri čemu je količina 4-PBA smanjena za 10% do 50% u usporedbi sa sastavom koji obuhvaća efikasnu količinu 4-PBA koja ne sadrži TUDCA.
4. Sastav za upotrebu prema patentnom zahtjevu 1, pri čemu je subjekt identificiran kao da ima najmanje jednu kopiju APOEε4 alela.
5. Sastav za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 4, pri čemu se TUDCA i 4-PBA primjenjuju odvojeno.
6. Sastav za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 4, pri čemu se TUDCA i 4-PBA primjenjuju zajedno.
7. Postupak smanjenja oksidativnog oštećenja izazvanog reaktivnim metabolitom kisika unutar stanice ex vivo, gdje postupak obuhvaća kontakt stanice sa tauroursodezoksikolnom kiselinom (TUDCA) ili njenom farmaceutski prihvatljivom soli i 4-fenilbuternom kiselinom (4-PBA) ili njenom farmaceutski prihvatljivom soli.
8. Postupak prema patentnom zahtjevu 7, pri čemu je stanica u kontaktu sa TUDCA u koncentraciji od oko 80 µM do oko 120 µM; i/ili, gdje je stanica u kontaktu sa 4-PBA u koncentraciji od oko 0.8 mM do oko 1.2 mM.
9. Postupak prema patentnim zahtjevima 7 ili 8, pri čemu:
a) stanica predstavlja stanicu sisavca;
b) stanica predstavlja ljudsku stanicu; ili
c) je stanica neuron.
10. Tauroursodezoksikolna kiselina (TUDCA) ili njena farmaceutski prihvatljiva sol i 4-fenilbutirična kiselina (4-PBA) ili njena farmaceutski prihvatljiva sol za upotrebu u postupku liječenja neurodegenerativnog oboljenja u vezi sa oksidativnim oštećenjem izazvanim reaktivnim metabolitom kisika kod subjekta, gdje postupak obuhvaća identifikaciju subjekta koji ima neurodegenerativno oboljenje u vezi sa oksidativnim oštećenjem izazvanim reaktivnim metabolitom kisika; gdje se spomenutom subjektu daje TUDCA ili njena farmaceutski prihvatljiva sol i 4-PBA ili farmaceutski prihvatljiva sol, pri čemu se količina 4-PBA koja se primjenjuje u kombinaciji sa TUDCA smanjuje za 10% do 50% u usporedbi sa time kada se daje samo 4-PBA.
11. Tauroursodezoksikolna kiselina (TUDCA) ili njena farmaceutski prihvatljiva sol za upotrebu u postupku liječenja neurodegenerativnog oboljenja u vezi sa oksidativnim oštećenjem izazvanim reaktivnim metabolitom kisika kod subjekta, pri čemu postupak obuhvaća identifikaciju subjekta koji ima neurodegenerativno oboljenje u vezi sa oksidativnim oštećenjem izazvanim reaktivnim metabolitom kisika; davanje datom subjektu TUDCA ili njene farmaceutski prihvatljive soli i 4-PBA ili njene farmaceutski prihvatljive soli, gdje se količina 4-PBA koja se primjenjuje u kombinaciji sa TUDCA smanjuje za 10% do 50% u usporedbi sa time kada se daje samo 4-PBA.
12. 4-fenilbutirična kiselina (4-PBA) ili njena farmaceutski prihvatljiva sol za upotrebu u postupku liječenja neurodegenerativnog oboljenja kod subjekta povezanog sa oksidativnim oštećenjem izazvanim reaktivnim metabolitom kisika, gdje postupak obuhvaća identifikaciju subjekta koji ima neurodegenerativno oboljenje u vezi sa oksidativnim oštećenjem izazvanim reaktivnim metabolitom kisika; davanje datom subjektu TUDCA ili njene farmaceutski prihvatljive soli i 4-PBA ili njene farmaceutski prihvatljive soli, gdje se količina 4-PBA koja se primjenjuje u kombinaciji sa TUDCA smanjuje za 10% do 50% u usporedbi sa time kada se daje samo 4-PBA.
13. TUDCA ili njena farmaceutski prihvatljiva sol i 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 10, TUDCA ili njena farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 11, ili 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 12, pri čemu se TUDCA i 4-PBA pojedinačno daju u odvojenim doznim oblicima; i po slobodnom izboru, pri čemu se dozni oblici za TUDCA i/ili 4-PBA daju odvojeno ili zajedno, kao pojedinačna dnevna doza, na dnevnoj ili tjednoj bazi.
14. Sastav za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 6, TUDCA ili njena farmaceutski prihvatljiva sol i 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema patentnim zahtjevima 10 ili 13, TUDCA ili njena farmaceutski prihvatljiva sol za upotrebu prema patentnim zahtjevima 11 ili 13, ili 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema patentnim zahtjevima 12 ili 13, gdje se TUDCA primjenjuje u količini od oko 10mg/po kg tjelesne težine, oko 15mg/po kg tjelesne težine, oko 20mg/po kg tjelesne težine, oko 30mg/ po kg tjelesne težine, ili oko 40mg/ po kg tjelesne težine i gdje se 4-PBA daje u količini od oko 10mg/ po kg tjelesne težine, oko 30 mg/kg tjelesne težine, oko 50 mg/kg tjelesne težine, oko 100 mg/kg tjelesne težine, oko 200 mg/kg tjelesne težine, ili oko 400mg/kg tjelesne težine.
15. Sastav za upotrebu prema patentnom zahtjevu 1, TUDCA ili njena farmaceutski prihvatljiva sol i 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 10 i 13 do 14, TUDCA ili njena farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 11 i 13 do 14, ili 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva od 12 do 14, pri čemu je neurodegenerativno oboljenje odabrano iz grupe koju čine Alzheimerova bolest, Huntingtonova bolest, Parkinsonova bolest, amiotrofična lateralna skleroza, Pickova bolest (Pickova demencija), multi-infarktna demencija, Creutzfeldt-Jakobova bolest, demencija sa Lewijevim tijelima, miješana demencija, i frontotemporalna demencija.
16. Sastav za upotrebu prema patentnom zahtjevu 1, TUDCA ili njena farmaceutski prihvatljiva sol i 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 10 i 13 do 15, TUDCA ili njena farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 11 i 13 do 15, ili 4-PBA ili njena farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 12 do 15, pri čemu je subjekt životinja, sisavac ili čovjek.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361804690P | 2013-03-24 | 2013-03-24 | |
| US14/140,083 US9872865B2 (en) | 2013-03-24 | 2013-12-24 | Compositions for improving cell viability and methods of use thereof |
| EP14775675.3A EP2978419B1 (en) | 2013-03-24 | 2014-02-24 | Compositions for improving cell viability and methods of use thereof |
| PCT/US2014/018040 WO2014158547A1 (en) | 2013-03-24 | 2014-02-24 | Compositions for improving cell viability and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200990T1 true HRP20200990T1 (hr) | 2020-10-16 |
Family
ID=51569584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200990TT HRP20200990T1 (hr) | 2013-03-24 | 2020-06-23 | Sastavi za poboljšanje stanične vijabilnosti i postupci za njihovu upotrebu |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US9872865B2 (hr) |
| EP (2) | EP3750531A1 (hr) |
| JP (5) | JP6495237B2 (hr) |
| KR (6) | KR20230164242A (hr) |
| CN (3) | CN105050593B (hr) |
| AU (4) | AU2014242123B2 (hr) |
| CA (1) | CA2908683A1 (hr) |
| CY (1) | CY1123092T1 (hr) |
| DK (1) | DK2978419T3 (hr) |
| ES (1) | ES2796250T3 (hr) |
| HK (1) | HK1216851A1 (hr) |
| HR (1) | HRP20200990T1 (hr) |
| HU (1) | HUE051105T2 (hr) |
| LT (1) | LT2978419T (hr) |
| ME (1) | ME03747B (hr) |
| PL (1) | PL2978419T3 (hr) |
| PT (1) | PT2978419T (hr) |
| RS (1) | RS60596B1 (hr) |
| SI (1) | SI2978419T1 (hr) |
| WO (1) | WO2014158547A1 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| US10934244B2 (en) * | 2015-06-15 | 2021-03-02 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
| KR101743960B1 (ko) * | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
| EP3347486A4 (en) * | 2015-09-09 | 2019-06-19 | The Trustees of Columbia University in the City of New York | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE |
| JP2019526612A (ja) * | 2016-09-12 | 2019-09-19 | スティーブン・ホフマン | 認知症を治療するための組成物 |
| US20210293794A1 (en) * | 2017-02-24 | 2021-09-23 | University Of Hawii Cancer Center | Metabolic biomarkers for the identification and characterization of alzheimers disease |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN113164421A (zh) * | 2018-12-18 | 2021-07-23 | 参天制药株式会社 | 含有4-苯基丁酸的老视的治疗或预防剂 |
| CA3140042A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| US11583542B2 (en) * | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| MX2022007276A (es) * | 2019-12-16 | 2023-04-25 | Amylyx Pharmaceuticals Inc | Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas. |
| IL295562A (en) * | 2020-02-13 | 2022-10-01 | Prilenia Neurotherapeutics Ltd | Treatment of muscular dystrophy (ALS) by combining pridopidine and another active substance |
| US10905698B1 (en) * | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| WO2022188029A1 (zh) * | 2021-03-09 | 2022-09-15 | 兆科药业（广州）有限公司 | 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物 |
| WO2022191296A1 (ja) * | 2021-03-10 | 2022-09-15 | 昭和電工マテリアルズ株式会社 | 培地組成物、細胞培養物の製造方法、及び細胞懸濁物 |
| CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
| CN113349300A (zh) * | 2021-06-07 | 2021-09-07 | 湖南农业大学 | 4-苯基丁酸在制备猪肠道保健产品中的应用 |
| WO2023081482A1 (en) * | 2021-11-08 | 2023-05-11 | Amylyx Pharmaceuticals, Inc. | Combination of turso and sodium phenyl butyrate for the treatment of neurodegenerative diseases |
| WO2023102149A1 (en) * | 2021-12-02 | 2023-06-08 | MarvelBiome, Inc. | Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions |
| US20230277630A1 (en) | 2022-03-02 | 2023-09-07 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| US20230364110A1 (en) * | 2022-05-12 | 2023-11-16 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| US20230372263A1 (en) | 2022-05-17 | 2023-11-23 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| WO2024015286A1 (en) * | 2022-07-11 | 2024-01-18 | AI Therapeutics, Inc. | Apilimod combination therapy |
| WO2024015281A1 (en) * | 2022-07-11 | 2024-01-18 | AI Therapeutics, Inc. | Apilimod combination therapy |
| US20240100069A1 (en) | 2022-09-07 | 2024-03-28 | Amylyx Pharmaceuticals, Inc. | Methods and Compositions for Treating Amyotrophic Lateral Sclerosis |
| US20240139211A1 (en) | 2022-09-29 | 2024-05-02 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| WO2024095118A1 (en) | 2022-10-31 | 2024-05-10 | Novartis Ag | Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis |
| WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| WO2004096123A2 (en) | 2003-04-02 | 2004-11-11 | Regents Of The University Of Minnesota | Methods of promoting cell viability |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| CN101048164B (zh) | 2004-11-01 | 2012-05-09 | 柳署弘 | 降低肌萎缩性侧索硬化中神经变性的组合物 |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| EP1871385A1 (en) | 2005-02-10 | 2008-01-02 | Regents Of The University Of Minnesota | Methods for treating visual disorders |
| CA2679608A1 (en) | 2006-03-22 | 2007-10-04 | President And Fellows Of Harvard College | Methods and compositions for treating hypercholesterolemia and atherosclerosis |
| US7737175B2 (en) | 2007-06-01 | 2010-06-15 | Duke University | Methods and compositions for regulating HDAC4 activity |
| ES2332687B1 (es) | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| CA2723833A1 (en) | 2008-05-12 | 2009-11-19 | Umut Ozcan | Methods and compositions for the treatment of obesity |
| US20110142799A1 (en) | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| US20120157419A1 (en) | 2009-02-02 | 2012-06-21 | Tuvia Gilat | Methods and compositions for treating alzheimer's disease |
| EP2422787A1 (en) | 2010-08-17 | 2012-02-29 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
| US9632075B2 (en) | 2011-11-01 | 2017-04-25 | Meselex, Inc. | Prevention or attenuation of neuropathic pain by bile acids |
| EP2599477A1 (en) | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| WO2013142490A2 (en) | 2012-03-20 | 2013-09-26 | Metselex, Inc. | Tauroursodeoxycholic acid attenuates or abolishes formation and deposition of amyloid-b peptide |
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| DK3016654T3 (en) | 2013-07-01 | 2018-11-05 | Bruschettini Srl | TAUROURODEOXYCHOLIC ACID (TUDCA) FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS |
| US10142799B2 (en) | 2014-08-19 | 2018-11-27 | Qualcomm Incorporated | Multicasting traffic using multi-connectivity |
-
2013
- 2013-12-24 US US14/140,083 patent/US9872865B2/en active Active
-
2014
- 2014-02-24 RS RS20200676A patent/RS60596B1/sr unknown
- 2014-02-24 AU AU2014242123A patent/AU2014242123B2/en active Active
- 2014-02-24 ME MEP-2020-117A patent/ME03747B/me unknown
- 2014-02-24 KR KR1020237040555A patent/KR20230164242A/ko active Application Filing
- 2014-02-24 SI SI201431557T patent/SI2978419T1/sl unknown
- 2014-02-24 JP JP2016505464A patent/JP6495237B2/ja active Active
- 2014-02-24 CN CN201480017771.XA patent/CN105050593B/zh active Active
- 2014-02-24 PL PL14775675T patent/PL2978419T3/pl unknown
- 2014-02-24 LT LTEP14775675.3T patent/LT2978419T/lt unknown
- 2014-02-24 DK DK14775675.3T patent/DK2978419T3/da active
- 2014-02-24 KR KR1020227037260A patent/KR102607635B1/ko active IP Right Grant
- 2014-02-24 KR KR1020217041070A patent/KR102396714B1/ko active IP Right Grant
- 2014-02-24 PT PT147756753T patent/PT2978419T/pt unknown
- 2014-02-24 KR KR1020217005747A patent/KR20210025134A/ko not_active Application Discontinuation
- 2014-02-24 WO PCT/US2014/018040 patent/WO2014158547A1/en active Application Filing
- 2014-02-24 EP EP20169399.1A patent/EP3750531A1/en active Pending
- 2014-02-24 CN CN201910114290.5A patent/CN109999043B/zh active Active
- 2014-02-24 ES ES14775675T patent/ES2796250T3/es active Active
- 2014-02-24 HU HUE14775675A patent/HUE051105T2/hu unknown
- 2014-02-24 KR KR1020227015333A patent/KR102460746B1/ko active IP Right Grant
- 2014-02-24 EP EP14775675.3A patent/EP2978419B1/en active Active
- 2014-02-24 CA CA2908683A patent/CA2908683A1/en active Pending
- 2014-02-24 CN CN201911065687.6A patent/CN110787169B/zh active Active
- 2014-02-24 KR KR1020157030684A patent/KR102223250B1/ko active IP Right Grant
-
2016
- 2016-04-27 HK HK16104836.2A patent/HK1216851A1/zh unknown
-
2017
- 2017-12-11 US US15/837,866 patent/US10251896B2/en active Active
-
2019
- 2019-01-31 AU AU2019200658A patent/AU2019200658B2/en active Active
- 2019-02-20 US US16/280,861 patent/US11071742B2/en active Active
- 2019-03-06 JP JP2019040563A patent/JP6766198B2/ja active Active
-
2020
- 2020-02-04 US US16/781,239 patent/US10857162B2/en active Active
- 2020-04-02 US US16/838,975 patent/US20200230156A1/en not_active Abandoned
- 2020-06-23 HR HRP20200990TT patent/HRP20200990T1/hr unknown
- 2020-06-30 CY CY20201100604T patent/CY1123092T1/el unknown
- 2020-09-16 JP JP2020155505A patent/JP7080944B2/ja active Active
-
2021
- 2021-03-22 AU AU2021201770A patent/AU2021201770B2/en active Active
- 2021-11-02 US US17/516,845 patent/US20220160733A1/en active Pending
- 2021-12-21 US US17/557,606 patent/US20220110948A1/en not_active Abandoned
-
2022
- 2022-05-25 JP JP2022085433A patent/JP7242945B2/ja active Active
- 2022-08-23 AU AU2022221410A patent/AU2022221410A1/en active Pending
-
2023
- 2023-03-08 JP JP2023035423A patent/JP2023085274A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200990T1 (hr) | Sastavi za poboljšanje stanične vijabilnosti i postupci za njihovu upotrebu | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| BR112015027682A2 (pt) | Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente | |
| SG10201909122QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NZ778131A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| IN2015DN00376A (hr) | ||
| BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
| BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| MX2022015141A (es) | Composiciones y metodos de uso de un compuesto de control de inapetencia. | |
| BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| HRP20171532T1 (hr) | Apoekvorin za smanjenje neuronalne ozljede uvjetovane ishemijom | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| WO2012106058A3 (en) | Animal treatments | |
| BR112013018296A2 (pt) | tratamento de disfunções cognitivas em esquizofrenia | |
| BR112012020377A2 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| JP2015521647A5 (hr) | ||
| BR112015022084A2 (pt) | composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol | |
| BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto |